391 related articles for article (PubMed ID: 30717708)
1. Impact of in vitro driven expression signatures of CD133 stem cell marker and tumor stroma on clinical outcomes in gastric cancers.
Kim TM; Ko YH; Ha SJ; Lee HH
BMC Cancer; 2019 Feb; 19(1):119. PubMed ID: 30717708
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of putative markers of cancer stem cells in gastric cancer: A retrospective cohort study.
Chen XL; Chen XZ; Wang YG; He D; Lu ZH; Liu K; Zhang WH; Wang W; Li CC; Xue L; Zhao LY; Yang K; Liu JP; Zhou ZG; Hu JK; Mo XM
Oncotarget; 2016 Sep; 7(38):62049-62069. PubMed ID: 27557490
[TBL] [Abstract][Full Text] [Related]
3. CD133+/CD166+ human gastric adenocarcinoma cells present the properties of neoplastic stem cells and emerge more malignant features.
Ni T; Wang H; Zhan D; Tao L; Lv M; Wang W; Chu Z; Zhou Z; Sunagawa M; Liu Y
Life Sci; 2021 Mar; 269():119021. PubMed ID: 33450261
[TBL] [Abstract][Full Text] [Related]
4. CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors.
Rocco A; Liguori E; Pirozzi G; Tirino V; Compare D; Franco R; Tatangelo F; Palaia R; D'Armiento FP; Pollastrone G; Affuso A; Bottazzi EC; Masone S; Persico G; Nardone G
J Cell Physiol; 2012 Jun; 227(6):2686-93. PubMed ID: 21898409
[TBL] [Abstract][Full Text] [Related]
5. [Sorting of CD133(+) subset cells in human gastric cancer and the identification of their tumor initiating cell-like properties].
Lu RQ; Wu JG; Zhou GC; Jiang HG; Yu JW; Jiang BJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Feb; 15(2):174-9. PubMed ID: 22368028
[TBL] [Abstract][Full Text] [Related]
6. In vitro characterization of CD133
Nair RM; Balla MM; Khan I; Kalathur RKR; Kondaiah P; Vemuganti GK
BMC Cancer; 2017 Nov; 17(1):779. PubMed ID: 29162051
[TBL] [Abstract][Full Text] [Related]
7. Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem-cell like characteristics.
Kanwal R; Shukla S; Walker E; Gupta S
Cancer Lett; 2018 Aug; 430():25-33. PubMed ID: 29775627
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of leucine-rich-repeat-containing G-protein-coupled receptor 5, an intestinal stem cell marker, in gastric carcinomas.
Jang BG; Lee BL; Kim WH
Gastric Cancer; 2016 Jul; 19(3):767-77. PubMed ID: 26386561
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.
Joseph C; Arshad M; Kurozomi S; Althobiti M; Miligy IM; Al-Izzi S; Toss MS; Goh FQ; Johnston SJ; Martin SG; Ellis IO; Mongan NP; Green AR; Rakha EA
Breast Cancer Res Treat; 2019 Apr; 174(2):387-399. PubMed ID: 30554343
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow-derived mesenchymal stem cells increase drug resistance in CD133-expressing gastric cancer cells by regulating the PI3K/AKT pathway.
Ji N; Yu JW; Ni XC; Wu JG; Wang SL; Jiang BJ
Tumour Biol; 2016 Nov; 37(11):14637-14651. PubMed ID: 27619680
[TBL] [Abstract][Full Text] [Related]
11. LGR5 Is a Gastric Cancer Stem Cell Marker Associated with Stemness and the EMT Signature Genes NANOG, NANOGP8, PRRX1, TWIST1, and BMI1.
Wang B; Chen Q; Cao Y; Ma X; Yin C; Jia Y; Zang A; Fan W
PLoS One; 2016; 11(12):e0168904. PubMed ID: 28033430
[TBL] [Abstract][Full Text] [Related]
12. CD133 expression is correlated with chemoresistance and early recurrence of gastric cancer.
Lee HH; Seo KJ; An CH; Kim JS; Jeon HM
J Surg Oncol; 2012 Dec; 106(8):999-1004. PubMed ID: 22674531
[TBL] [Abstract][Full Text] [Related]
13. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
14. Sequential expression of putative stem cell markers in gastric carcinogenesis.
Wang T; Ong CW; Shi J; Srivastava S; Yan B; Cheng CL; Yong WP; Chan SL; Yeoh KG; Iacopetta B; Salto-Tellez M
Br J Cancer; 2011 Aug; 105(5):658-65. PubMed ID: 21829201
[TBL] [Abstract][Full Text] [Related]
15. Emerging roles of CD133 in the treatment of gastric cancer, a novel stem cell biomarker and beyond.
Soleimani A; Dadjoo P; Avan A; Soleimanpour S; Rajabian M; Ferns G; Ryzhikov M; Khazaei M; Hassanian SM
Life Sci; 2022 Mar; 293():120050. PubMed ID: 35026215
[TBL] [Abstract][Full Text] [Related]
16. The Intestinal Stem Cell Marker SMOC2 Is an Independent Prognostic Marker Associated With Better Survival in Gastric Cancer.
Hyun CL; Park SJ; Kim HS; Song HJ; Kim HU; Lee C; Lee DH; Maeng YH; Kim YS; Jang B
Anticancer Res; 2021 Jul; 41(7):3689-3698. PubMed ID: 34230168
[TBL] [Abstract][Full Text] [Related]
17. CD133 in brain tumor: the prognostic factor.
Li B; McCrudden CM; Yuen HF; Xi X; Lyu P; Chan KW; Zhang SD; Kwok HF
Oncotarget; 2017 Feb; 8(7):11144-11159. PubMed ID: 28055976
[TBL] [Abstract][Full Text] [Related]
18. Thyroid cancer stem-like cells and epithelial-mesenchymal transition in thyroid cancers.
Hardin H; Montemayor-Garcia C; Lloyd RV
Hum Pathol; 2013 Sep; 44(9):1707-13. PubMed ID: 23528862
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-598 inhibits the growth and maintenance of gastric cancer stem-like cells by down-regulating RRS1.
Ma Y; Yan F; Wei W; Deng J; Li L; Liu L; Sun J
Cell Cycle; 2019 Oct; 18(20):2757-2769. PubMed ID: 31438772
[TBL] [Abstract][Full Text] [Related]
20. CXCR4 is involved in CD133-induced EMT in non-small cell lung cancer.
Tu Z; Xie S; Xiong M; Liu Y; Yang X; Tembo KM; Huang J; Hu W; Huang X; Pan S; Liu P; Altaf E; Kang G; Xiong J; Zhang Q
Int J Oncol; 2017 Feb; 50(2):505-514. PubMed ID: 28000861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
